---
document_datetime: 2023-09-21 22:02:10
document_pages: 10
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/empliciti-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: empliciti-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 6.4935342
conversion_datetime: 2025-12-29 22:48:54.231305
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Empliciti

Procedural steps taken and scientific information after the authorisation

| Application   | Scope                                                                                                                                                                               | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary   |
|---------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|-----------|
| IB/0035       | B.II.f.1.b.5 - Stability of FP - Extension of the shelf life of the finished product - Biological/immunological medicinal product in accordance with an approved stability protocol | 01/06/2023                          |                                             | SmPC                             |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| IA/0034             | A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient                                                                                                                                                                                                                                                                          | 03/03/2023   |            | Annex II              |                                   |
|---------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|------------|-----------------------|-----------------------------------|
| IA/0033/G           | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.I.b.1.c - Change in the specification parameters and/or limits of an AS, starting material/intermediate/reagent - Addition of a new specification parameter to the specification with its corresponding test method | 11/11/2022   | n/a        |                       |                                   |
| IA/0032             | B.II.d.2.a - Change in test procedure for the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                                                                                                                                          | 11/11/2022   | n/a        |                       |                                   |
| PSUSA/10500 /202111 | Periodic Safety Update EU Single assessment - elotuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 07/07/2022   | n/a        |                       | PRAC Recommendation - maintenance |
| IAIN/0030/G         | This was an application for a group of variations. A.4 - Administrative change - Change in the name and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or                                                                                                                                                                                                                                                                                                           | 15/02/2022   | 14/10/2022 | SmPC, Annex II and PL |                                   |

<div style=\"page-break-after: always\"></div>

|                     | intermediate used in the manufacture of the AS or manufacturer of a novel excipient A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                                                  |            |            |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0029             | B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                                                                                                                    | 10/01/2022 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                             |
| II/0028             | C.I.4 : Update of section 5.1 of the SmPC in order to update efficacy data from the final CSR for study CA204125. This is a open label, randomized phase 2 Trial of Pomalidomide/Dexamethasone With or Without Elotuzumab in RRMM. In addition, the MAH took the opportunity to remove the list of local representatives in the Package Leaflet and update the address of the manufacturer. C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data | 21/10/2021 | 14/10/2022 | SmPC, Annex II and PL | SmPC new text Section 5.1 'A pre-planned final OS analysis was performed after at least 78 deaths occurred. The minimum follow-up was 45.0 months. The OS results at final analysis reached statistical significance. A significantly longer OS was observed in patients in the E-Pd arm compared to patients in the Pd arm (HR = 0.59; 95% CI: 0.37, 0.93; p value 0.0217).' For more information, please refer to the Summary of Product Characteristics. |
| PSUSA/10500 /202011 | Periodic Safety Update EU Single assessment - elotuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                      | 08/07/2021 | n/a        |                       | PRAC Recommendation - maintenance                                                                                                                                                                                                                                                                                                                                                                                                                           |
| II/0026             | B.I.b.2.d - Change in test procedure for AS or starting material/reagent/intermediate - Substantial change to or replacement of a                                                                                                                                                                                                                                                                                                                                                                             | 03/06/2021 | n/a        |                       |                                                                                                                                                                                                                                                                                                                                                                                                                                                             |

<div style=\"page-break-after: always\"></div>

|                     | biological/immunological/immunochemical test method or a method using a biological reagent for a biological AS                                                                                                                                                                                                      |            |            |                                  |                                                                                                                                                                                                                                                                         |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|----------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IB/0027             | B.II.b.3.a - Change in the manufacturing process of the finished or intermediate product - Minor change in the manufacturing process                                                                                                                                                                                | 31/03/2021 | n/a        |                                  |                                                                                                                                                                                                                                                                         |
| R/0024              | Renewal of the marketing authorisation.                                                                                                                                                                                                                                                                             | 15/10/2020 | 17/12/2020 | SmPC, Annex II, Labelling and PL | Based on the review of data on quality, safety and efficacy, the CHMP considered that the benefit-risk balance of Empliciti in the approved indication remains favourable and therefore recommended the renewal of the marketing authorisation with unlimited validity. |
| PSUSA/10500 /201911 | Periodic Safety Update EU Single assessment - elotuzumab                                                                                                                                                                                                                                                            | 09/07/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| IAIN/0023           | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release                                                                                                                                                                                          | 20/04/2020 | 19/10/2020 | Annex II and PL                  |                                                                                                                                                                                                                                                                         |
| PSUSA/10500 /201905 | Periodic Safety Update EU Single assessment - elotuzumab                                                                                                                                                                                                                                                            | 16/01/2020 | n/a        |                                  | PRAC Recommendation - maintenance                                                                                                                                                                                                                                       |
| II/0020/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.I.a.1.j - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Replacement or addition of a site where batch control/testing takes place and any of the test | 10/10/2019 | n/a        |                                  |                                                                                                                                                                                                                                                                         |

<div style=\"page-break-after: always\"></div>

|           | method at the site is a biol/immunol method                                                                                                                                                                                                                                                                                                                                             |            |            |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
|-----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| II/0019/G | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites B.II.b.2.b - Change to importer, batch release arrangements and quality control testing of the FP - Replacement/addition of a site where batch control/testing takes place for a biol/immunol product and any of the test methods at the site is a biol/immunol method | 03/10/2019 | n/a        |             |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |
| II/0018   | Update of section 5.1 of the SmPC with final overall survival data from study CA204004 (A Phase 3, Randomized, Open Label Trial of lenalidomide/dexamethasone With or Without Elotuzumab in Relapsed or Refractory Multiple Myeloma). C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                 | 26/09/2019 | 19/10/2020 | SmPC        | Overall survival (OS) was a secondary endpoint in study CA204004 and the final OS analysis was pre-planned to occur after at least 427 deaths. The final OS analysis was performed after 212 deaths in the Elotuzumab/lenalidomide/dexamethasone (E Ld) arm and 225 deaths in the lenalidomide/dexamethasone (Ld) arm. The minimum follow up was 70.6 months (clinical cut-off date of 03-Oct-2018). A statistically significant advantage in OS was observed in patients in the E Ld arm compared to patients in the Ld arm. The median OS in the E Ld arm was 48.30 months compared with 39.62 months in the Ld arm. Patients in the E Ld arm had an 18% reduction in the risk of death compared with those in the Ld arm (HR = 0.82; 95.4% CI: 0.68, 1.00; p value = 0.0408). |
| II/0012   | Extension of Indication to include treatment in combination with pomalidomide and dexamethasone for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at                                                                                                                                                                                  | 25/07/2019 | 23/08/2019 | SmPC and PL | Please refer to the Scientific Discussion - Empliciti-H-C- 3967-II-0012                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |

<div style=\"page-break-after: always\"></div>

|                     | least two prior therapies including lenalidomide and a proteasome inhibitor and have demonstrated disease progression on the last therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.6, 4.8, 4.9, 5.1, 5.2 and 6.6 of the SmPC are updated. The Package Leaflet is updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet. The RMP (version 2.1) is updated to reflect the new indication. C.I.6.a - Change(s) to therapeutic indication(s) - Addition of a new therapeutic indication or modification of an approved one   |            |     |                                   |
|---------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|-----------------------------------|
| IB/0017/G           | This was an application for a group of variations. B.I.d.1.a.4 - Stability of AS - Change in the re-test period/storage period - Extension or introduction of a re-test period/storage period supported by real time data B.I.d.1.c - Stability of AS - Change in the re-test period/storage period or storage conditions - Change to an approved stability protocol                                                                                                                                                                                                                                                                        | 29/07/2019 | n/a |                                   |
| PSUSA/10500 /201811 | Periodic Safety Update EU Single assessment - elotuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    | 14/06/2019 | n/a | PRAC Recommendation - maintenance |
| IB/0016             | B.II.d.1.a - Change in the specification parameters and/or limits of the finished product - Tightening of specification limits                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              | 25/04/2019 | n/a |                                   |

<div style=\"page-break-after: always\"></div>

| II/0013             | B.II.b.2.c.3 - Change to importer, batch release arrangements and quality control testing of the FP - Including batch control/testing for a biol/immunol product and any of the test methods is a biol/immunol/immunochemical method                                                                                                                                                                                                                                                                       | 28/02/2019   | 02/04/2019   | Annex II and PL        |                                   |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|------------------------|-----------------------------------|
| IG/1059             | A.1 - Administrative change - Change in the name and/or address of the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                 | 15/02/2019   | 02/04/2019   | SmPC, Labelling and PL |                                   |
| PSUSA/10500 /201805 | Periodic Safety Update EU Single assessment - elotuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 17/01/2019   | n/a          |                        | PRAC Recommendation - maintenance |
| PSUSA/10500 /201711 | Periodic Safety Update EU Single assessment - elotuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 14/06/2018   | n/a          |                        | PRAC Recommendation - maintenance |
| PSUSA/10500 /201705 | Periodic Safety Update EU Single assessment - elotuzumab                                                                                                                                                                                                                                                                                                                                                                                                                                                   | 11/01/2018   | n/a          |                        | PRAC Recommendation - maintenance |
| IB/0009/G           | This was an application for a group of variations. B.I.a.1.f - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - Changes to quality control testing arrangements for the AS -replacement or addition of a site where batch control/testing takes place B.I.b.2.e - Change in test procedure for AS or starting material/reagent/intermediate - Other changes to a test procedure (including replacement or addition) for the AS or a starting material/intermediate | 08/01/2018   | n/a          |                        |                                   |

<div style=\"page-break-after: always\"></div>

| II/0006             | C.I.4 - Change(s) in the SPC, Labelling or PL due to new quality, preclinical, clinical or pharmacovigilance data                                                                                                                                          | 13/07/2017   | 04/10/2017   | SmPC                              |
|---------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|-----------------------------------|
| PSUSA/10500 /201611 | Periodic Safety Update EU Single assessment - elotuzumab                                                                                                                                                                                                   | 09/06/2017   | n/a          | PRAC Recommendation - maintenance |
| IA/0007/G           | This was an application for a group of variations. A.7 - Administrative change - Deletion of manufacturing sites A.7 - Administrative change - Deletion of manufacturing sites                                                                             | 23/05/2017   | n/a          |                                   |
| IA/0005             | B.I.b.2.a - Change in test procedure for AS or starting material/reagent/intermediate - Minor changes to an approved test procedure                                                                                                                        | 09/03/2017   | n/a          |                                   |
| PSUSA/10500 /201605 | Periodic Safety Update EU Single assessment - elotuzumab                                                                                                                                                                                                   | 12/01/2017   | n/a          | PRAC Recommendation - maintenance |
| II/0003             | B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal product and is not related to a protocol | 24/11/2016   | n/a          |                                   |
| II/0001/G           | This was an application for a group of variations. 1) IA -A.6 - to add the ATC Code following granting                                                                                                                                                     | 10/11/2016   | 04/10/2017   | SmPC, Annex Labelling             |

<div style=\"page-break-after: always\"></div>

<!-- image -->

| by WHO in the SmPC and with the latest QRD template 2) II- B.I.a.1.e - to add active substance manufacturer. 3) IB- B.I.a.1.f -to add alternative in-process testing samples for Mycoplasma, and MVM (Minute Virus 4) II- B.I.a.3.c - to increase of elotuzumab drug substance 25,000 L at BMS-Devens 5) IB -B.I.a.4.b - to implement control for Triton X-100 BMS-Devens sites. 6) II-B.I.a.4.d - to widen limits from â‰¤ 347 L/m2 A.6 - Administrative change Code/ATC Vet Code B.I.a.1.e - Change in the starting material/reagent/intermediate change relates to a biological material [-] used in the biological/immunological B.I.a.1.f - Change in the starting material/reagent/intermediate Changes to quality control the AS -replacement or batch control/testing takes B.I.a.3.c - Change in batch ranges) of AS or intermediate   |
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

<div style=\"page-break-after: always\"></div>

| biological/immunological AS B.I.a.4.b - Change to in-process tests or limits applied during the manufacture of the AS - Addition of a new in-process test and limits B.I.a.4.d - Change to in-process tests or limits applied during the manufacture of the AS - Widening of the approved in-process test limits, which may have a significant effect on the overall quality of the AS   |
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|